Status: Recruiting
Safety and Efficacy of RN1201 Injection as First-Line Treatment for Newly Diagnosed Multiple Myeloma
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-targeted allogeneic CAR-T cell therapy, in patients with newly diagnosed multiple myeloma. Patients will receive lymphodepletion followed by a single infusion of RN1201. Primary endpoints include incidence and severity of treatment-emergent adverse events. Secondary endpoints assess response rate and minimal residual disease (MRD) status.
Participants needed: 18
Trial details
Phase: Phase 1Age: 18-70Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital of Soochow UniversityUpdated: Jun 16, 2026Locations: 1
Eligibility criteria
Willingness to participate in the trial and provide written informed consent. [+9]
Patients with serious active infections. [+10]